CDC25C

Across TCGA pan-cancer cohorts, CDC25C mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDC25C data layer compared with 30 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDC25C mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CDC25C expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where CDC25C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.629	0.976	.004	15	view →
LSCC	DFS	Median	All	0.915	0.284	.006	9	view →
LUAD	OS	Median	II,III,IV	0.273	0.831	.027	2	view →
HNSC	DFS	Median	All	0.487	0.811	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDC25C–PDAC (OS)

Open the PDAC breakdown →